All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 24, 2022
Home » Topics » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Abbvie U.S. headquarters

Stepping out: Abbvie decides alpha-synuclein deal with Bioarctic is over

April 20, 2022
By Lee Landenberger
No Comments
Abbvie Inc. is stepping away from a 2016 deal with Bioarctic AB to develop alpha-synuclein antibodies for treating Parkinson’s disease, originally valued at up to $775 million. Bioarctic said it plans to stay the course without its big-pocketed partner. Bioarctic’s stock (Stockholm:BIOA-B) fell 14.6% to SEK90 (US$9.40) on April 20.
Read More
Chess board and pieces, blocks spelling out M&A

Skin in the game: Regeneron buys Checkmate for $250M

April 19, 2022
By Lee Landenberger
No Comments
Regeneron Pharmaceuticals Inc. proposes to buy Checkmate Pharmaceuticals Inc. though an all-cash price of $10.50 per share for about $250 million. That’s pretty much on target with Checkmate’s April 19 closing share price (NASDAQ:CMPI) of $10.35, as the stock gained a staggering 326% on the day.
Read More
Handshake in office setting

Biopharma deal values rise by 36% in Q1, while M&As are at lowest point

April 19, 2022
By Karen Carey
No Comments
Although efforts focused on COVID-19 continue to fade and there are fewer collaborations than in previous years, the biopharma industry has recorded record value from mega-deals in the first quarter (Q1) of 2022, topping all recent years, as executives continue to opt against costly mergers and acquisitions.
Read More
Knee pain illustration

Juniper Biologics acquires gene therapy for knee osteoarthritis in $600M deal from Kolon Life Science

April 19, 2022
By David Ho and Gina Lee
No Comments
Through a $600 million deal, Juniper Biologics Pte. Ltd. has acquired rights from Kolon Life Science Inc. to develop and commercialize TG-C LD (Tissuegene-C low dose) for the treatment of knee osteoarthritis. Singapore-based Juniper will hold the rights for Asia Pacific, the Middle East and Africa and be responsible for developing and commercializing the candidate within those regions.
Read More

Ji Xing wins greater China rights to Lenz’s presbyopia drugs in $110M deal

April 19, 2022
By Doris Yu
No Comments
Ji Xing Pharmaceuticals Ltd. has acquired greater China rights to two candidates from Lenz Therapeutics Inc. for the treatment of presbyopia in greater China in a deal worth up to $110 million. San Diego-based Lenz will receive $15 million in up-front payments, up to $95 million in regulatory and commercial milestone payments, and potential royalty payments based on net sales.
Read More
Natus logo, teal background overlaying medical concept image

Natus Medical investors sense a sweet payout with Archimed’s acquisition offer of $1.2B

April 18, 2022
By Annette Boyle
No Comments
Health care-focused private equity firm Archimed Group agreed to acquire Natus Medical Inc. for $33.50 per share, a nearly 29% premium over the April 14 closing share price for the provider of medical devices to diagnose and treat neurological and sensory disorders. The deal will take Natus (NASDAQ:NTUS) private after more than 20 years as a publicly traded company.
Read More
Nonprofit stamp

Nonprofit deal and grant values decline by 57%

April 18, 2022
By Karen Carey
No Comments
In a return to the pre-pandemic days, biopharma deals with nonprofit or government entities and industry grants appear to be tracking closer to 2019 figures, as the flurry of activity over the last two years dissipates. Through mid-April in 2022, BioWorld has tracked 246 bio/nonprofit deals worth $1.02 billion, and a total of 86 grants valued at $328.13 million.
Read More

Ji Xing wins greater China rights to Lenz’s presbyopia drugs in $110M deal

April 14, 2022
By Doris Yu
No Comments
Ji Xing Pharmaceuticals Ltd. has acquired greater China rights to two candidates from Lenz Therapeutics Inc. for the treatment of presbyopia in greater China in a deal worth up to $110 million. San Diego-based Lenz will receive $15 million in up-front payments, up to $95 million in regulatory and commercial milestone payments, and potential royalty payments based on net sales.
Read More
Knee pain illustration

Juniper Biologics acquires gene therapy for knee osteoarthritis in $600M deal from Kolon Life Science

April 14, 2022
By David Ho and Gina Lee
No Comments
Through a $600 million deal, Juniper Biologics Pte. Ltd. has acquired rights from Kolon Life Science Inc. to develop and commercialize TG-C LD (Tissuegene-C low dose) for the treatment of knee osteoarthritis. Singapore-based Juniper will hold the rights for Asia Pacific, the Middle East and Africa and be responsible for developing and commercializing the candidate within those regions.
Read More
Woman working at computer in laboratory

Clinisys purchases cloud-based laboratory system Apollolims

April 13, 2022
By Catherine Longworth
No Comments
Diagnostic testing group Clinisys Inc. has acquired cloud-based laboratory operations software company Apollolims in an undisclosed deal. Headquartered in Chertsey, U.K., and Tucson, Ariz., Clinisys will expand its public health, toxicology, and molecular diagnostics offering through the acquisition. The deal builds on the company’s combination with Sunquest and Horizon announced in January.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 … 135 136 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 23, 2022.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for May 23.
  • China U.S. deal

    Merck acquires global rights to cancer drug from Kelun in $1.4B deal

    BioWorld
    In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for...
  • Lung cancer illustration

    Acea Pharma fails to win green light for abivertinib in China

    BioWorld
    Zhejiang Acea Pharmaceutical Co. Ltd. failed to obtain marketing approval from China’s NMPA for its third-generation EGFR tyrosine kinase inhibitor, abivertinib....
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing